AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

AMO-Pharma-Limited

More Like This

AMO Pharma Announces Update on Scientific Advice for Registrational Clinical Study of AMO-02 in Congenital Myotonic Dystrophy Type 1 Following Meetings with the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency and Health Canada

PR Newswire associated0

AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1

PR Newswire associated0

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

PR Newswire associated0

AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy

PR Newswire associated0

AMO Pharma Enters into License Agreement with Population Health Research Institute (PHRI) and Venca Research Inc. to Advance Largest-Ever Study in Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease

Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025